- Presentations to cover clinical and
preclinical data on pipeline candidates in Company’s thyroid eye
disease program, including lead candidate VRDN-001 -
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that multiple abstracts featuring clinical and
preclinical data on the Company’s pipeline candidates for the
treatment of thyroid eye disease (TED) will be presented at the
following medical meetings:
- The 45th Annual Meeting of the European Thyroid Association
(ETA) to be held September 9-12, 2023, in Milan, Italy
- The 41st Annual Meeting of the European Society of Ophthalmic
Plastic and Reconstructive Surgery (ESOPRS) to be held September
14-16, 2023, in Naples, Italy
- The Annual Meeting of the American Thyroid Association (ATA) to
be held September 27-October 1, 2023, in Washington, DC
Presentations at all three conferences will highlight clinical
and pharmacologic data from studies of VRDN-001, a full antagonist
antibody to the insulin-like growth factor-1 receptor (IGF-1R), in
development for TED. An additional presentation will feature
pharmacokinetic data for VRDN-003, a next-generation, half-life
extended antibody to IGF-1R for TED. The Company will also present
clinical pharmacodynamic responses to VRDN-001 in healthy
volunteers and patients with active TED.
Conference: ETA
Title:
VRDN-001, a Full Antagonist Antibody to
IGF-1 Receptor: In Vitro Pharmacology and Phase 1/2 Results
in Patients with Thyroid Eye Disease
Session:
Oral Session 9—Thyroid Eye Disease
Information:
Monday, September 11, 2023, 2:40 to 2:52
pm CET
Title:
Preclinical Pharmacokinetics and
Clinical Exposure Prediction for VRDN-003, a Next-Generation
Half-life Extended Antibody to IGF-1R for Thyroid Eye
Disease
Session:
Oral Session 9—Thyroid Eye Disease
Information:
Monday, September 11, 2023, 2:52 to 3:04
pm CET
Conference: ESOPRS
Title:
In Vitro Pharmacology and Phase 1/2
Results of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor
for Thyroid Eye Disease
Session:
Oral Communications: Orbit
Information:
Friday, September 15, 2023, 2:20 to 2:25
pm CET
Title:
VRDN-001, a Full Antagonist Antibody to
IGF-1R: Proof-of-Concept Results in Chronic TED
Session:
Oral Communications: Orbit/Socket
Information:
Saturday, September 16, 2023, 9:35 to 9:40
am CET
Conference: ATA
Title:
In Vitro Pharmacology and Phase 1/2
Results of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor
for Thyroid Eye Disease
Session:
Oral Abstracts Session 3: Effects and
Treatment of Autoimmune TED
Information:
Thursday, September 28, 2023, 1:50 to 2:50
pm EDT
Title:
Pharmacodynamic Responses to VRDN-001,
a Full Antagonist Antibody to IGF-1 Receptor in Development for
Thyroid Eye Disease (TED) in Healthy Volunteers and Patients with
Active TED
Session:
Poster Review
Information:
Thursday, September 28, 2023, 10:30 am to
6:00 pm EDT
Following their respective presentations, the above abstracts
will be posted at
www.viridiantherapeutics.com/pipeline/scientific-presentations.
About Viridian’s Thyroid Eye Disease Pipeline (VRDN-001,
-002, and -003)
Viridian’s lead product candidate, VRDN-001, is a differentiated
monoclonal antibody targeting insulin-like growth factor-1 receptor
(IGF-1R), a clinically and commercially validated target for the
treatment of thyroid eye disease (TED). In preclinical studies,
VRDN-001 was shown to be a full antagonist of IGF-1R, with more
complete receptor blockade than other anti-IGF-1R antibodies,
including the only currently approved TED therapy. Data from the
Phase 2 portion of the ongoing trial established clinical
proof-of-concept for VRDN-001 in patients with active and chronic
TED. VRDN-001 was generally well tolerated in the trial. The THRIVE
Phase 3 trial in patients with active TED is ongoing. The Company
is currently planning to start its second Phase 3 trial, called
THRIVE-2, in patients with chronic TED.
The Company is also advancing three candidates (VRDN-001,
VRDN-002, and VRDN-003 subcutaneous (SC)) designed for
administration as convenient, low-volume, SC injections for the
treatment of TED.
Viridian’s goal is to potentially bring a best-in-class
intravenous therapy followed by a first- and best-in-class SC
therapy to the market for the treatment of the TED.
VRDN-001, -002, and -003 are investigational therapies that are
not approved for any use in any country.
About TED
TED is a serious and debilitating rare autoimmune disease that
causes inflammation within the orbit of the eye that can cause
double vision, pain, and potential blindness. TED is a progressive
disease consisting of an initial active phase, followed by a
transition to a secondary chronic phase. More than 50,000 and
200,000 people are estimated to suffer from active and chronic TED,
respectively, in the United States and Europe.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on
engineering and developing potential best-in-class medicines for
patients with serious and rare diseases. Viridian’s expertise in
antibody discovery and engineering enables it to develop
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The Company
is conducting its first global Phase 3 trial called THRIVE to
evaluate the safety and efficacy of VRDN-001 in patients with
active TED. Viridian is also planning a second Phase 3 trial,
called THRIVE-2, to evaluate the safety and efficacy of VRDN-001 in
patients with chronic TED. In addition to its program for
intravenously administered VRDN-001, the Company is advancing three
candidates for its subcutaneous strategy with the goal of providing
a more conveniently administered therapy to patients with TED.
Viridian is also developing multiple preclinical assets in
autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and Twitter.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as, but not limited to, "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "might," "plan,"
"potential," "predict," "project," "should," "target," "will," or
"would" or other similar terms or expressions that concern our
expectations, plans and intentions. Forward-looking statements
include, without limitation, statements regarding our expectations,
strategies, plans and intentions. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based on our current beliefs, expectations, and
assumptions. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. No representations or warranties (expressed or
implied) are made about the accuracy of any such forward-looking
statements. Such forward-looking statements are subject to a number
of material risks and uncertainties including but not limited to:
the potential efficacy and safety of VRDN-001, VRDN-002, and
VRDN-003 for the treatment of Thyroid Eye Disease (TED), the
results of ongoing or future clinical trials; the timing, progress
and plans for our ongoing or future research, pre-clinical and
clinical development programs; including the clinical trials for
VRDN-001, VRDN-002, and VRDN-003 and other risks and uncertainties,
including those risks set forth under the caption "Risk Factors" in
our Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on August 8, 2023 and other subsequent
disclosure documents filed with the SEC. Any forward-looking
statement speaks only as of the date on which it was made. Neither
the Company, nor its affiliates, advisors, or representatives,
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230907907028/en/
Investors: Louisa Stone, 508-808-2400 Manager, Investor
Relations IR@viridiantherapeutics.com
Media: Matt Fearer, 617-272-4605 Vice President, Corporate
Communications Media@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024